Michele Jonsson Funk, PhD, FISPE

UNC Gillings School of Global Public Health
Chapel Hill, North Carolina, United States

Michele Jonsson Funk, PhD, FISPE, is Associate Professor of Epidemiology, Head of the pharmacoepidemiology program at UNC, and Director of the Center for Pharmacoepidemiology. Over the past 16 years on faculty at UNC, her research has focused on the intersection of pharmacoepidemiology and methods for estimating valid effects in real world data with specific applications in women’s health research. Her ongoing research studies use data from US Medicare claims, IBM Watson Health Analytics’ Marketscan data, and the Carolina Data Warehouse for Health (CDW-H) – an electronic medical record warehouse that brings together rich clinical and administrative data on over 2 million patients seen across the spectrum of care by providers in the UNC Health Care System. More recently, she has led efforts at UNC to link complementary data (e.g. Medicare claims with the UNC CDW-H). Her methodologic expertise includes rigorous estimation of drug effects using non-experimental data, evaluation of treatment effect heterogeneity, implementation of propensity scores, doubly robust estimators, causal inference methods, and data linkage approaches. Her applied research spans a number of substantive areas including cardiovascular disease, cancer, and women’s health including effects of prenatal drug exposures on pregnancy outcomes.

Abbvie (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received, Collaborative agreement with Center for Pharmacoepidemiology, UNC)Boehringer Ingelheim (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received, Collaborative agreement with Center for Pharmacoepidemiology, UNC)GlaxoSmithKline (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received, Collaborative agreement with Center for Pharmacoepidemiology, UNC)GlaxoSmithKline (Consultant/Advisory Board, All compensation paid to UNC (my employer))Takeda (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received, Collaborative agreement with Center for Pharmacoepidemiology, UNC)UCB (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received, Collaborative agreement with Center for Pharmacoepidemiology, UNC)

Presentation(s):

• Intermediate Pharmacoepidemiology: Approaches to Unmeasured Confounders

  Thursday, August 25, 2022
  8:30 AM – 12:30 PM CEST

• Heterogeneous Treatment Effect of Glucagon-like Peptide 1 Receptor Agonists on Asthma/COPD exacerbation: Machine-learning Analysis of Two Nationwide Cohorts

  Friday, August 26, 2022
  2:00 PM – 2:15 PM CEST

• Translation of a Medicare Claims-based Frailty Index from International Classification of Diseases 9th Revision to 10th Revision

  Friday, August 26, 2022
  2:00 PM – 2:15 PM CEST

• Risk Ratios versus Hazard Ratios in Comparative Effectiveness Research: An Illustration Using Clinical Trial Data

  Friday, August 26, 2022
  2:00 PM – 2:15 PM CEST

• Considerations of Misclassification and Confounding on COVID-19 Vaccines Effectiveness Studies - A Vaccine SIG Endorsed Symposium

  Friday, August 26, 2022
  3:30 PM – 5:00 PM CEST

• Validation of an International Classification of Disease (ICD) 10 Algorithm for Hypoglycemia in Administrative Claims Data

  Sunday, August 28, 2022
  8:30 AM – 8:45 AM CEST

• Using Iterative Causal Forest to Identify Heterogeneous Treatment Effects: Sodium-glucose Cotransporter-2 inhibitors versus Glucagon-like Peptide-1 Receptor Agonists on Hospitalization for Heart Failure

  Sunday, August 28, 2022
  9:45 AM – 10:00 AM CEST

• Individualized Treatment Rule Identification in Heart Failure Patients Using Precision-medicine Methods

  Sunday, August 28, 2022
  2:15 PM – 2:20 PM CEST